Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Durect (DRRX – Research Report), Alaunos Therapeutics (TCRT – Research Report) and Marinus (MRNS – Research Report).
Durect (DRRX)
H.C. Wainwright analyst Ed Arce maintained a Buy rating on Durect today and set a price target of $32.00. The company’s shares closed last Tuesday at $4.75.
According to TipRanks.com, Arce is a 5-star analyst with an average return of
Currently, the analyst consensus on Durect is a Moderate Buy with an average price target of $32.00.
See Insiders’ Hot Stocks on TipRanks >>
Alaunos Therapeutics (TCRT)
H.C. Wainwright analyst Swayampakula Ramakanth maintained a Hold rating on Alaunos Therapeutics today. The company’s shares closed last Tuesday at $0.60, close to its 52-week low of $0.41.
According to TipRanks.com, Ramakanth has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Alaunos Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $2.15.
Marinus (MRNS)
Ladenburg Thalmann & Co. analyst Michael Higgins maintained a Buy rating on Marinus today and set a price target of $17.00. The company’s shares closed last Tuesday at $7.04.
According to TipRanks.com, Higgins is a 3-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Marinus with a $22.00 average price target, representing a 210.3% upside. In a report released today, JMP Securities also reiterated a Buy rating on the stock with a $18.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on DRRX:
